Association between preoperative biologic use and surgical morbidity in patients with Crohn's disease.
Biologics
Crohn’s disease
Morbidity
Surgery
Surgical site infection
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
26
03
2022
pubmed:
7
4
2022
medline:
10
5
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
We evaluated the influence of preoperative treatments with biologics on surgical morbidity in patients with Crohn's disease (CD). We reviewed the surveillance data of patients with CD who underwent surgery between April 2018 and April 2021. The possible risk factors for morbidity were analyzed. A total of 305 surgically treated patients were included. Anti-TNF alpha agents and ustekinumab were used in 92 and 27 patients, respectively, within 12 weeks before surgery. There were no cases of mortality. In total, 70/305 (23.0%) patients developed a complication, and 42/305 (13.8%) patients developed a surgical site infection (SSI) (17 incisional SSIs and 35 organ/space SSIs). Current smoking status (OR 3.44), emergent/urgent surgery (OR 6.85), and abdominoperineal resection (APR) (OR 14.93) were identified as risk factors for total complications. Penetrating disease (OR 14.55) was identified as a risk factor for incisional SSIs. Current smoking status (OR 7.09), an American Society of Anesthesiologists (ASA) score greater than 3 (OR 5.85), a postoperative blood sugar level over 155 mg/dL (OR 4.37), and APR (OR 207.95) were identified as risk factors for organ/space SSIs. No correlation between preoperative treatment with biologics and surgical mortality or morbidity was found. However, we should perform further analyses on a larger number of patients because the analyses may be limited by selection bias for treatment and several confounding factors.
Identifiants
pubmed: 35384495
doi: 10.1007/s00384-022-04140-8
pii: 10.1007/s00384-022-04140-8
doi:
Substances chimiques
Biological Products
0
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1010Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Van Assche G, Rutgeerts P (2000) Anti-TNF agents in Crohn’s disease. Expert Opin Investig Drugs 9:103–111
doi: 10.1517/13543784.9.1.103
Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549
doi: 10.1016/S0140-6736(02)08512-4
Stidham RW, Lee TC, Higgins PD et al (2014) Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 39:1349–1362
doi: 10.1111/apt.12749
Xu Y, Yang L, An P et al (2019) Meta-analysis: the influence of preoperative infliximab use on postoperative complications of Crohn’s disease. Inflamm Bowel Dis 25:261–269
doi: 10.1093/ibd/izy246
Lin YS, Cheng SW, Wang YH et al (2019) Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumor necrosis factor agents for Crohn’s disease. Aliment Pharmacol Ther 49:966–977
doi: 10.1111/apt.15184
Adamina M, Bonovas S, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis 14:155–168
doi: 10.1093/ecco-jcc/jjz187
Lightner AL, McKenna NP, Tse CS et al (2018) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis 12:402–407
doi: 10.1093/ecco-jcc/jjx163
Shim HH, Ma C, Kotze PG et al (2018) Preoperative ustekinumab treatment is not associated with increased postoperative complications in Crohn’s disease: a Canadian multi-centre observational cohort study. J Can Assoc Gastroenterol 1:115–123
doi: 10.1093/jcag/gwy013
Garg R, Mohan BP, Ponnada S et al (2021) Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn’s disease: a systematic review and meta-analysis. Ann Gastroenterol 34:691–698
pubmed: 34475740
pmcid: 8375651
García MJ, Rivero M, Miranda-Bautista J et al (2021) Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of Geteccu. J Clin Med 10:4402
doi: 10.3390/jcm10194402
Smith RL, Bohl JK, McElearney ST et al (2004) Wound infection after elective colorectal resection. Ann Surg 239:599–607
doi: 10.1097/01.sla.0000124292.21605.99
Louis E, Collard A, Oger AF et al (2001) Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777–782
doi: 10.1136/gut.49.6.777
Uchino M, Ikeuchi H, Bando T et al (2019) Efficacy of preoperative oral antibiotic prophylaxis for the prevention of surgical site infections in patients with Crohn’s disease: a randomized controlled trial. Ann Surg 269:420–426
doi: 10.1097/SLA.0000000000002567
Dindo D, Demartines N et al (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Culver DH, Horan TC, Gaynes RP et al (1991) Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am J Med 91:152S-158S
doi: 10.1016/0002-9343(91)90361-Z
Horan TC, Gaynes RP, Martone WJ et al (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608
doi: 10.2307/30148464
Narula N, Charleton D, Marshall JK (2013) Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 37:1057–1064
doi: 10.1111/apt.12313
Ganesh Kumar N, Khouri AN, Byrn JC et al (2021) The role of autologous flap reconstruction in patients with Crohn’s disease undergoing abdominoperineal resection. Dis Colon Rectum 64:429–437
doi: 10.1097/DCR.0000000000001844
Pędziwiatr M, Mavrikis J, Witowski J et al (2018) Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. Med Oncol 35:95
doi: 10.1007/s12032-018-1153-0
Global guidelines for the prevention of surgical site infection. http://apps.who.int/iris/bitstream/10665/250680/1/9789241549882-eng.pdf . Accessed 1 Dec 2016
Oshima T, Takesue Y, Ikeuchi H et al (2013) Preoperative oral antibiotics and intravenous antimicrobial prophylaxis reduce the incidence of surgical site infections in patients with ulcerative colitis undergoing IPAA. Dis Colon Rectum 56:1149–1155
doi: 10.1097/DCR.0b013e31829f71a0
Cornillie F, Shealy D, D’Haens G et al (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 5:463–473
doi: 10.1046/j.1365-2036.2001.00956.x